Log In
Print
BCIQ
Print
Print this Print this
 

SB623

  Manage Alerts
Collapse Summary General Information
Company SanBio Co. Ltd.
DescriptionAllogeneic cells derived from genetically engineered bone marrow stromal cells obtained from healthy adult donors
Molecular Target
Mechanism of ActionCell therapy
Therapeutic ModalityCell therapy

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$205.0M

$6.0M

$199.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today